Samchundang Pharm's Latast Expands Market Share to 11%... The Growing Preservative-Free Single-Dose Glaucoma Eye Drop Market
Samchundang Pharm (000250)'s glaucoma treatment 'Latast Eye Drops' has recorded a double-digit market share in the domestic latanoprost single-dose eye drop market. As competition among new products grows increasingly fierce, the product is expanding its presence in the market, centered on hospital

Samchundang Pharm (000250)'s glaucoma treatment 'Latast Eye Drops' has recorded a double-digit market share in the domestic latanoprost single-dose eye drop market. As competition among new products grows increasingly fierce, the product is expanding its presence in the market, centered on hospital and clinic prescriptions.
■ Market Share Rises from 3.1% to 11.0% in Just Over a Year
According to data compiled by market research firm UBIST, Latast's share of the market stood at 11.0% as of August 2026. This is a 7.9 percentage point increase compared to 3.1% in March 2025. Over the same period, its share in the hospital and clinic channel rose from 4.8% to 14.2%, showing a higher level than the overall market.
■ Market Size Grows 2.7-Fold Over Four Years
The market in which Latast competes has itself continued to grow. The size of the domestic latanoprost single-dose eye drop market expanded from 13.1 billion won in 2021 to 36 billion won in 2025, roughly 2.7 times larger over four years. Last year, four new products, including Latast, entered the market, intensifying competition among products.
Samchundang Pharm cited growing demand for preservative-free single-dose formulations as the background to this trend. Due to the nature of glaucoma treatment, which requires long-term use of eye drops, demand for preservative-free products is increasing, and in both domestic and international latanoprost markets, formulation choices are shifting from multi-dose to single-dose products.
■ A Generic Ten Years in the Making... Non-Inferiority Confirmed in Global Phase 3 Trial
The company began preparing for the development of single-dose latanoprost about ten years ago. Latast is a generic drug approved after the expiration of the original product's patent, and during development, the company conducted not only physicochemical equivalence evaluations but also a global phase 3 clinical trial.
According to the company, the clinical trial was conducted over 12 weeks, comparing against the original drug in 170 patients with open-angle glaucoma or ocular hypertension. The mean intraocular pressure in the Latast treatment group decreased by approximately 32%, from 24.4 mmHg to 16.6 mmHg, confirming non-inferiority compared to the comparator drug.
■ In Europe, Sold as a 'Original Brand' by a Global Pharmaceutical Company
Overseas, the company supplies finished products to a global pharmaceutical company that holds the original drug. According to Samchundang Pharm, the same Latast product prescribed in Korea is sold in Europe under the pharmaceutical company's original brand. It is a structure in which the company supplies its self-developed generic product to the company holding the original drug.
■ A Preservative-Free Latanoprost Formulation Dosed Once Daily
Latast is a preservative-free eye drop containing latanoprost. It works by promoting the outflow of aqueous humor in the eye to lower intraocular pressure, and is administered once a day. The storage conditions specified by the company are room temperature of 1-30°C, and the usable period after opening the aluminum pouch is 30 days.
Samchundang Pharm assessed that its development and production capabilities, prepared in line with the market shift toward single-dose formulations, are leading to expanded domestic prescriptions and overseas supply. Going forward, the company plans to broaden its prescription base in the domestic market while strengthening its supply position in overseas markets, including Europe.
[This article is for informational purposes only and does not recommend the use of any specific medication or the purchase or sale of any specific stock. Market share figures and clinical results should be interpreted according to data compilation standards and trial conditions. Medication use and storage should follow approved labeling and the guidance of medical professionals and pharmacists, and investment decisions and any resulting responsibility rest with the investor. AI assistance was used in writing this article.]
CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.
![[Breaking] Cyberattack via Optimizely Exposes 178 Global Organizations... CNN, BBC, HSBC, and Ledger Also Affected](/_next/image?url=https%3A%2F%2Fmedia.cbcglobe.com%2Ftenants%2Fcbc00000-0000-4000-8000-000000000001%2Fmedia%2Fcbc%2F2026%2F11%2F627874%2Ffc472b72a2596aa1%2Fvariants%2Fhero.webp&w=1920&q=75)


